Granulocytic Myeloid-Derived Suppressor Cells as Negative Regulators of Anticancer Immunity.
antitumor immunity
immune suppression
immunotherapy
polymorphonuclear myeloid-derived suppressor cells
tumor progression
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
05
2020
accepted:
21
07
2020
entrez:
28
9
2020
pubmed:
29
9
2020
medline:
20
4
2021
Statut:
epublish
Résumé
The immune system plays a critical role in cancer progression and response to therapy. However, the immune system can be compromised during the neoplastic process. Notably, the myeloid lineage, which gives rise to granulocytic cells, including neutrophils, is a well-recognized target of tumor-mediated immune suppression. Ordinarily, granulocytic cells are integral for host defense, but in neoplasia the normal process of granulocyte differentiation (i.e., granulopoiesis) can be impaired leading instead to the formation of granulocytic (or PMN)-myeloid-derived suppressor cells (MDSCs). Such cells comprise various stages of myeloid differentiation and are defined functionally by their highly pro-tumorigenic and immune suppressive activities. Thus, considerable interest has been devoted to impeding the negative contributions of PMN-MDSCs to the antitumor response. Understanding their biology has the potential to unveil novel therapeutic opportunities to hamper PMN-MDSC production in the bone marrow, their mobilization, or their effector functions within the tumor microenvironment and, therefore, bolster anticancer therapies that require a competent myeloid compartment. In this review, we will highlight mechanisms by which the neoplastic process skews granulopoiesis to produce PMN-MDSCs, summarize mechanisms by which they execute their pro-tumorigenic activities and, lastly, underscore strategies to obstruct their role as negative regulators of antitumor immunity.
Identifiants
pubmed: 32983128
doi: 10.3389/fimmu.2020.01963
pmc: PMC7481329
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1963Subventions
Organisme : NCI NIH HHS
ID : F30 CA254327
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA172105
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA085183
Pays : United States
Informations de copyright
Copyright © 2020 Kramer and Abrams.
Références
Cancer Immunol Res. 2018 Nov;6(11):1352-1363
pubmed: 30171135
Oncotarget. 2017 Jun 11;8(34):55804-55820
pubmed: 28915554
Cancer Immunol Immunother. 2013 May;62(5):909-18
pubmed: 23589106
Nat Rev Cancer. 2004 Feb;4(2):97-105
pubmed: 14964307
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Front Immunol. 2019 Sep 26;10:2293
pubmed: 31616443
Cancer Res. 2010 Jun 1;70(11):4335-45
pubmed: 20484028
Clin Cancer Res. 2008 Dec 15;14(24):8270-8
pubmed: 19088044
Cell. 2006 Nov 3;127(3):469-80
pubmed: 17081971
J Leukoc Biol. 2011 Feb;89(2):311-7
pubmed: 21106641
Front Immunol. 2019 Jul 17;10:1661
pubmed: 31379854
Cancer Immunol Res. 2019 Feb;7(2):282-291
pubmed: 30514791
Cell. 1996 Oct 18;87(2):307-17
pubmed: 8861914
Cell Rep. 2018 Dec 11;25(11):3036-3046.e6
pubmed: 30540937
Immunol Cell Biol. 2017 Jan;95(1):42-55
pubmed: 27430527
Am J Respir Crit Care Med. 2018 Sep 15;198(6):777-787
pubmed: 29617574
Cancer Res. 2010 Aug 1;70(15):6139-49
pubmed: 20631080
Cancer Res. 2017 Jun 1;77(11):2834-2843
pubmed: 28381543
Blood. 2003 Jan 1;101(1):305-10
pubmed: 12393690
Nat Med. 2006 Oct;12(10):1191-7
pubmed: 17063141
Immunity. 2010 Jun 25;32(6):790-802
pubmed: 20605485
Blood. 2008 Apr 15;111(8):4233-44
pubmed: 18272812
Annu Rev Immunol. 2003;21:759-806
pubmed: 12615892
Clin Cancer Res. 2018 Oct 1;24(19):4834-4844
pubmed: 29914893
Nat Rev Immunol. 2013 Mar;13(3):159-75
pubmed: 23435331
J Hematol Oncol. 2017 May 5;10(1):101
pubmed: 28476164
J Immunol. 2008 Oct 15;181(8):5791-802
pubmed: 18832739
J Immunol. 2017 May 15;198(10):4129-4139
pubmed: 28356386
Blood. 1998 Feb 1;91(3):863-9
pubmed: 9446646
Oncotarget. 2017 Jan 10;8(2):3649-3665
pubmed: 27690299
Cell Rep. 2013 May 30;3(5):1617-28
pubmed: 23623495
J Leukoc Biol. 2017 Aug;102(2):191-200
pubmed: 28476751
Oral Oncol. 2019 Aug;95:157-163
pubmed: 31345384
J Leukoc Biol. 2014 Nov;96(5):685-93
pubmed: 24929004
Cancer Res. 2015 Dec 1;75(23):5070-83
pubmed: 26450912
J Clin Invest. 2013 Apr;123(4):1580-9
pubmed: 23454751
Nat Rev Cancer. 2009 Nov;9(11):798-809
pubmed: 19851315
Int Immunopharmacol. 2009 Jul;9(7-8):900-9
pubmed: 19336265
J Biol Chem. 2013 Jun 28;288(26):19103-15
pubmed: 23677993
Immunity. 2013 Mar 21;38(3):541-54
pubmed: 23477736
Int J Hematol. 2015 Apr;101(4):342-51
pubmed: 25749660
J Immunol. 2002 Aug 1;169(3):1261-9
pubmed: 12133947
Clin Cancer Res. 2020 Mar 15;26(6):1420-1431
pubmed: 31848188
Front Immunol. 2018 Mar 02;9:398
pubmed: 29552012
Cancer Res. 2016 Apr 15;76(8):2125-36
pubmed: 26880800
Blood Adv. 2017 Oct 10;1(22):1923-1933
pubmed: 29296839
J Immunol. 2016 Feb 1;196(3):1419-29
pubmed: 26740106
Cancer Immunol Immunother. 2009 Jan;58(1):49-59
pubmed: 18446337
Oncoimmunology. 2016 Mar 10;5(7):e1151591
pubmed: 27622015
Front Immunol. 2019 Aug 14;10:1912
pubmed: 31474989
Stem Cells. 2016 Aug;34(8):2026-39
pubmed: 27145382
Biochem Biophys Res Commun. 2020 Jul 23;528(2):330-335
pubmed: 32448508
Oncotarget. 2016 Jan 26;7(4):4760-9
pubmed: 26716894
Gastroenterology. 2012 Feb;142(2):219-32
pubmed: 22155636
Biochim Biophys Acta. 2014 Aug;1846(1):55-65
pubmed: 24727385
Nature. 2017 Mar 30;543(7647):728-732
pubmed: 28321130
Sci Rep. 2017 Oct 25;7(1):14048
pubmed: 29070836
Target Oncol. 2020 Apr;15(2):211-220
pubmed: 32207064
Immunity. 2014 May 15;40(5):785-800
pubmed: 24816404
Cancer Res. 2013 May 15;73(10):3007-18
pubmed: 23514705
Clin Exp Immunol. 2015 May;180(2):280-8
pubmed: 25476957
J Immunol. 2015 Mar 1;194(5):2369-79
pubmed: 25646302
Blood. 2003 Feb 1;101(3):961-9
pubmed: 12393459
Cancer Res. 2016 Sep 15;76(18):5241-52
pubmed: 27496709
J Immunol. 2016 Mar 1;196(5):2167-80
pubmed: 26810222
EMBO J. 1995 Mar 15;14(6):1166-75
pubmed: 7720707
J Immunol. 2008 Jun 15;180(12):7898-906
pubmed: 18523253
Oncotarget. 2016 Jun 21;7(25):37931-37943
pubmed: 27177328
Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):569-74
pubmed: 9012825
J Clin Invest. 2013 Oct;123(10):4464-78
pubmed: 24091328
Cancer Res. 2014 Feb 1;74(3):727-37
pubmed: 24351289
Cancer Res. 2009 Mar 15;69(6):2506-13
pubmed: 19244102
J Exp Med. 2016 May 2;213(5):827-40
pubmed: 27045006
Cancer Manag Res. 2019 Aug 02;11:7307-7315
pubmed: 31447588
Semin Oncol. 1996 Oct;23(5 Suppl 10):3-15
pubmed: 8893876
Immunity. 2016 Feb 16;44(2):303-15
pubmed: 26885857
Stem Cells. 2015 May;33(5):1630-41
pubmed: 25586960
Nat Rev Immunol. 2013 Jul;13(7):499-509
pubmed: 23787991
Front Oncol. 2019 Feb 21;9:48
pubmed: 30847297
Nat Immunol. 2006 Jul;7(7):732-9
pubmed: 16751774
Science. 1995 Aug 25;269(5227):1108-12
pubmed: 7652557
Clin Transl Immunology. 2016 Dec 23;5(12):e119
pubmed: 28090321
Int Immunopharmacol. 2018 Oct;63:282-291
pubmed: 30121453
J Exp Med. 2013 Oct 21;210(11):2239-56
pubmed: 24101380
Immunity. 2000 Aug;13(2):155-65
pubmed: 10981959
Mol Carcinog. 2018 Mar;57(3):429-439
pubmed: 29215754
Blood Adv. 2018 Jun 26;2(12):1459-1469
pubmed: 29941459
J Exp Med. 2013 Oct 21;210(11):2257-71
pubmed: 24127488
Leukemia. 2020 Mar;34(3):932-937
pubmed: 31586150
Nat Commun. 2017 Apr 06;8:14979
pubmed: 28382931
Cancer Res. 2009 Apr 15;69(8):3554-62
pubmed: 19351842
Blood. 2012 Mar 1;119(9):2003-12
pubmed: 22238324
Cell Death Dis. 2015 Nov 19;6:e1981
pubmed: 26583322
J Cell Mol Med. 2018 Feb;22(2):1070-1080
pubmed: 29218828